title: Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji.
abstract: BACKGROUND
  There is currently limited information about human papillomavirus (HPV) genotype distribution in women in the South Pacific region. This study's objective was to determine HPV genotypes present in cervical cancer (CC) and precancers (cervical intraepithelial lesion (CIN) 3) in Fiji.
  
  
  METHODS
  Cross-sectional analysis evaluated archival CC and CIN3 biopsy samples from 296 women of Melanesian Fijian ethnicity (n=182, 61.5%) and Indo-Fijian ethnicity (n=114, 38.5%). HPV genotypes were evaluated using the INNO-LiPA assay in archival samples from CC (n=174) and CIN3 (n=122) among women in Fiji over a 5-year period from 2003 to 2007.
  
  
  RESULTS
  Overall, 99% of the specimens tested were HPV DNA-positive for high-risk genotypes, with detection rates of 100%, 97.4% and 100% in CIN3, squamous cell carcinoma (SCC) and adenosquamous carcinoma biopsies, respectively. Genotypes 16 and 18 were the most common (77%), followed by HPV 31 (4.3%). Genotype HPV 16 was the most common identified (59%) in CIN3 specimens, followed by HPV 31 (9%) and HPV 52 (6.6%). Multiple genotypes were detected in 12.5-33.3% of specimens, depending on the pathology.
  
  
  CONCLUSIONS
  These results indicated that the two most prevalent CC-associated HPV genotypes in Fiji parallel those described in other regions worldwide, with genotype variations thereafter. These data suggest that the currently available bivalent and quadrivalent HPV vaccines could potentially reduce cervical cancers in Fiji by over 80% and reduce precancers by at least 60%.
authors.affiliation: Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Vic. 3052, Australia. Sepehr.tabrizi@thewomens.org.au
authors.forename: Sepehr N
authors.initials: SN
authors.lastname: Tabrizi
authors.forename: Irwin
authors.initials: I
authors.lastname: Law
authors.forename: Eka
authors.initials: E
authors.lastname: Buadromo
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Stevens
authors.forename: James
authors.initials: J
authors.lastname: Fong
authors.forename: Josaia
authors.initials: J
authors.lastname: Samuela
authors.forename: Mahomed
authors.initials: M
authors.lastname: Patel
authors.forename: E Kim
authors.initials: EK
authors.lastname: Mulholland
authors.forename: Fiona M
authors.initials: FM
authors.lastname: Russell
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Garland
mesh_terms: D018196:Carcinoma, Adenosquamous / Q000473:pathology / Q000821:virology; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000821:virology; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D003430:Cross-Sectional Studies; D004279:DNA, Viral / Q000235:genetics*; D005260:Female; D005367:Fiji; D005838:Genotype; D052162:Human papillomavirus 16 / Q000235:genetics; D052161:Human papillomavirus 18 / Q000235:genetics; D058952:Human papillomavirus 31 / Q000235:genetics; D006801:Humans; D009367:Neoplasm Staging; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000473:pathology* / Q000821:virology*
chemical_list: D004279:DNA, Viral